caa a22 4500 469121564 CHVBK 20180323133140.0 cr unu---uuuuu 170328e19920201xx s 000 0 eng 10.1007/BF02246239 doi (NATIONALLICENCE)springer-10.1007/BF02246239 Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects [Elektronische Daten] [J. Dingemanse, I. Berlin, C. Payan, H. Thiede, A. Puech] The effects of moclobemide and toloxatone, two reversible monoamine oxidase-A inhibitors, on biochemical parameters that reflect monoamine metabolism and on psychomotor performance parameters were investigated in a study in 12 healthy volunteers. Treatments were given double-blind in a randomised, placebo-controlled cross-over design, with 1 week wash-out between the treatments. Drugs were given thrice daily in the following doses: moclobemide 150-150-150 mg and toloxatone 400-200-400 mg. All assessments were performed on day 8 under standardized conditions. There was no difference with regard to adverse events between moclobemide and toloxatone: both drugs induced a slight decrease in both supine and standing heart rate. Judged on the basis of the area under the curve, the two MAO-inhibitors reduced the plasma levels of DHPG and HVA, with more pronounced effects for moclobemide than for toloxatone. After moclobemide MAO-A inhibition was almost constant over 24 h, whereas the effect of toloxatone was short lasting after each dose. The same differences were reflected in plasma 5-HIAA concentrations and urinary excretion of 3-methoxytyramine and normetanephine. Neither of the compounds tested had any influence on the memory, vigilance, mood, or sleeping habits of the subjects. Springer-Verlag, 1992 Moclobemide nationallicence Toloxatone nationallicence Monoamine oxidase-A nationallicence Psychometric performance nationallicence Dingemanse J. Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut Berlin I. Department of Clinical Pharmacology, Hôpital de la Salpêtrière, 47 BD. de L'Hôpital, F-75013, Paris, France aut Payan C. Department of Clinical Pharmacology, Hôpital de la Salpêtrière, 47 BD. de L'Hôpital, F-75013, Paris, France aut Thiede H. Klinikum Steglitz, I. medizinische Klinik, W-1000, Berlin 45, Germany aut Puech A. Department of Clinical Pharmacology, Hôpital de la Salpêtrière, 47 BD. de L'Hôpital, F-75013, Paris, France aut Psychopharmacology Springer-Verlag 106(1992-02-01), S68-S70 0033-3158 106<S68 1992 106 213 https://doi.org/10.1007/BF02246239 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02246239 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Dingemanse J. Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut NATIONALLICENCE 700 1- Berlin I. Department of Clinical Pharmacology, Hôpital de la Salpêtrière, 47 BD. de L'Hôpital, F-75013, Paris, France aut NATIONALLICENCE 700 1- Payan C. Department of Clinical Pharmacology, Hôpital de la Salpêtrière, 47 BD. de L'Hôpital, F-75013, Paris, France aut NATIONALLICENCE 700 1- Thiede H. Klinikum Steglitz, I. medizinische Klinik, W-1000, Berlin 45, Germany aut NATIONALLICENCE 700 1- Puech A. Department of Clinical Pharmacology, Hôpital de la Salpêtrière, 47 BD. de L'Hôpital, F-75013, Paris, France aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 106(1992-02-01), S68-S70 0033-3158 106<S68 1992 106 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer